Most FDA Advisers Recommend Avandia Stay On The Market

GAITHERSBURG, Md. - (Mealey's) A majority of Food and Drug Administration advisers voted July 14 to keep Avandia on the market but split on whether the anti-diabetes drug made by GlaxoSmithKline PLC (GSK) should carry additional warnings about its heart risks or that its use be restricted. Twelve...

$2.36B Glaxo Charge Covers Avandia, Paxil Litigation, Other Legal Costs

LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and the "vast majority" of Paxil product liability...